Information  X 
Enter a valid email address

Bowleven plc (BLVN)

  Print      Mail a friend       Annual reports

Monday 11 November, 2019

Bowleven plc

Block Admission Six Monthly Return

RNS Number : 7036S
Bowleven plc
11 November 2019
 

 

 

 

 

 

 

11 November 2019

 

Bowleven plc ('Bowleven')

 

 

Block Admission Six Monthly Return

                                                                                        

This Block Admission Six Monthly Return is intended to comply with the requirements of AIM Rule 29 and Schedule Six.

 

Name of company:

BOWLEVEN PLC

Name of scheme:

1)  BOWLEVEN PLC APPROVED CSOP SCHEME        (WITH UNAPPROVED SCHEDULE)

2)  BOWLEVEN PLC SCHEDULE 4 CSOP SCHEME        (WITH UNAPPROVED SCHEDULE)

Period of return:

From:

9 MAY 2019

To:

8 NOVEMBER 2019

Balance of unallotted securities under scheme(s) from previous return:

659,526

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

NIL

Less:  Number of securities issued/allotted under scheme(s) during period:

NIL

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

659,526

Number and class of share(s) (amount of stock/debit securities) originally admitted and the Date of Admission:

852,105 ORDINARY SHARES

9 MAY 2018

Total number of shares in issue at the end of the period:

335,272,933

 

 

ENQUIRIES

 

For further information, please contact:

 

Bowleven plc


Eli Chahin, Chief Executive

00 44 131 524 5678



Celicourt Communications Ltd


Mark Antelme

00 44 20 8434 2643

Jimmy Lea




Shore Capital & Corporate Ltd (NOMAD and Broker)


Robert Finlay

00 44 207 601 6100

Antonio Bossi

 


 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
BLRBUBDBXSGBGCR

a d v e r t i s e m e n t